Cover Image
市場調查報告書

Basilea Pharmaceutica AG : 產品平台分析

Basilea Pharmaceutica AG - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 251770
出版日期 內容資訊 英文 54 Pages
訂單完成後即時交付
價格
Back to Top
Basilea Pharmaceutica AG : 產品平台分析 Basilea Pharmaceutica AG - Product Pipeline Review - 2015
出版日期: 2015年09月16日 內容資訊: 英文 54 Pages
簡介

Basilea Pharmaceutica AG 是開發、推出抗生劑,抗真菌劑,抗癌藥的製藥公司。該公司的產品有嚴重型侵入性真菌感染疾病和潛在致死性抗藥性細菌感染疾病,多重抗藥性革蘭氏陰性菌,及癌症的治療藥。

這份報告提供 Basilea Pharmaceutica AG的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Basilea Pharmaceutica AG的基本資料

  • Basilea Pharmaceutica AG概要
  • 主要資訊
  • 企業資料

Basilea Pharmaceutica AG:R&D概要

  • 主要的治療範圍

Basilea Pharmaceutica AG:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Basilea Pharmaceutica AG:開發中產品概況

  • 最後階段的開發中產品
    • 登記前的產品/聯合治療模式
    • 申請不受理的/被撤消的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第Ⅱ期的產品/聯合治療模式
    • 第Ⅰ期的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Basilea Pharmaceutica AG:藥物簡介

Basilea Pharmaceutica AG:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Basilea Pharmaceutica AG:最近的開發平台趨勢

Basilea Pharmaceutica AG:暫停中的計劃

Basilea Pharmaceutica AG:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • BAL-2299

Basilea Pharmaceutica AG:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07586CDB

Summary

Global Markets Direct's, 'Basilea Pharmaceutica AG - Product Pipeline Review - 2015', provides an overview of the Basilea Pharmaceutica AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Basilea Pharmaceutica AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Basilea Pharmaceutica AG including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Basilea Pharmaceutica AG's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Basilea Pharmaceutica AG's pipeline products

Reasons to buy

  • Evaluate Basilea Pharmaceutica AG's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Basilea Pharmaceutica AG in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Basilea Pharmaceutica AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Basilea Pharmaceutica AG and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Basilea Pharmaceutica AG
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Basilea Pharmaceutica AG and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Basilea Pharmaceutica AG Snapshot
    • Basilea Pharmaceutica AG Overview
    • Key Information
    • Key Facts
  • Basilea Pharmaceutica AG - Research and Development Overview
    • Key Therapeutic Areas
  • Basilea Pharmaceutica AG - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Basilea Pharmaceutica AG - Pipeline Products Glance
    • Basilea Pharmaceutica AG - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Filing rejected/Withdrawn Products/Combination Treatment Modalities
    • Basilea Pharmaceutica AG - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Basilea Pharmaceutica AG - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Basilea Pharmaceutica AG - Drug Profiles
    • isavuconazonium sulfate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ceftobiprole medocaril
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BAL-101553
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BAL-30072
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BAL-3833
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CCT-196969
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CCT-241161
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Inflammatory Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Hematological and Solid Cancers
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Beta-Lactamase for Bacterial Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Basilea Pharmaceutica AG - Pipeline Analysis
    • Basilea Pharmaceutica AG - Pipeline Products by Target
    • Basilea Pharmaceutica AG - Pipeline Products by Route of Administration
    • Basilea Pharmaceutica AG - Pipeline Products by Molecule Type
    • Basilea Pharmaceutica AG - Pipeline Products by Mechanism of Action
  • Basilea Pharmaceutica AG - Recent Pipeline Updates
  • Basilea Pharmaceutica AG - Dormant Projects
  • Basilea Pharmaceutica AG - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • BAL-2299
  • Basilea Pharmaceutica AG - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Basilea Pharmaceutica AG, Key Information
  • Basilea Pharmaceutica AG, Key Facts
  • Basilea Pharmaceutica AG - Pipeline by Indication, 2015
  • Basilea Pharmaceutica AG - Pipeline by Stage of Development, 2015
  • Basilea Pharmaceutica AG - Monotherapy Products in Pipeline, 2015
  • Basilea Pharmaceutica AG - Out-Licensed Products in Pipeline, 2015
  • Basilea Pharmaceutica AG - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Basilea Pharmaceutica AG - Pre-Registration, 2015
  • Basilea Pharmaceutica AG - Filing rejected/Withdrawn, 2015
  • Basilea Pharmaceutica AG - Phase II, 2015
  • Basilea Pharmaceutica AG - Phase I, 2015
  • Basilea Pharmaceutica AG - Preclinical, 2015
  • Basilea Pharmaceutica AG - Discovery, 2015
  • Basilea Pharmaceutica AG - Pipeline by Target, 2015
  • Basilea Pharmaceutica AG - Pipeline by Route of Administration, 2015
  • Basilea Pharmaceutica AG - Pipeline by Molecule Type, 2015
  • Basilea Pharmaceutica AG - Pipeline Products by Mechanism of Action, 2015
  • Basilea Pharmaceutica AG - Recent Pipeline Updates, 2015
  • Basilea Pharmaceutica AG - Dormant Developmental Projects,2015
  • Basilea Pharmaceutica AG - Discontinued Pipeline Products, 2015
  • Basilea Pharmaceutica AG, Subsidiaries

List of Figures

  • Basilea Pharmaceutica AG - Pipeline by Top 10 Indication, 2015
  • Basilea Pharmaceutica AG - Pipeline by Stage of Development, 2015
  • Basilea Pharmaceutica AG - Monotherapy Products in Pipeline, 2015
  • Basilea Pharmaceutica AG - Out-Licensed Products in Pipeline, 2015
  • Basilea Pharmaceutica AG - Pipeline by Top 10 Target, 2015
  • Basilea Pharmaceutica AG - Pipeline by Top 10 Route of Administration, 2015
  • Basilea Pharmaceutica AG - Pipeline by Top 10 Molecule Type, 2015
  • Basilea Pharmaceutica AG - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top